Refine by
Research Based Clinical Mri Study Articles & Analysis: Older
14 news found
A key presentation highlights new clinical data on the novel development compound gadoquatrane, a next generation macrocyclic gadolinium-based contrast agent (GBCA) which is currently in Phase II of clinical development and planned to enter Phase III later this year. ...
ByBayer AG
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on symptom control, and quality of life. Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. Ms. Clyde is a highly experienced global business executive with an exceptional ...
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and advanced visualisation ...
Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users. The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD. OTTAWA, ON, March 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in ...
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the filing of a new patent application covering novel aspects of the DermaPrecise™ product portfolio as well ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that the company is expanding its scientific advisory board with the appointment of Jeff Sharman, M.D. and Clive Stanway, Ph.D. These two leaders in the field of cancer therapeutics will provide expert support and guidance as Araris continues preclinical and clinical development of its ...
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it’s clinical advisory team has completed the primary design of the next-phase clinical study of its skin rejuvenation product, RCS-01, to be conducted as part of ...
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The company has recently announced the fully-developed MALDI-Imaging Lipidomics Service to research the distribution of lipids in tissues. Lipidomics MALDI imaging mass ...
In Japan, clinical MRI scanners are available for the diagnosis and evaluation of dementia. ...
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japan’s Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture the Company’s RCT-01 cell therapy for ...
Additionally, results will be evaluated for possible correlations with findings on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), and cognitive performance measurements. “With this special eye scanner, it may be possible that in the future, research and maybe clinical applications can be done quickly and in a very ...
Ochsner Health System, GE Healthcare (NYSE: GE), and The Idea Village have launched today the “Wear Your Health” challenge. This challenge seeks to identify wearable technology concepts and mobile application solutions that can transform healthcare outcomes by addressing behavior management in patients with chronic disease. Starting today, individuals interested in participating can ...